{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:37:04Z","timestamp":1779338224817,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"ImmuVia, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93927-0","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T08:04:31Z","timestamp":1742630671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A bispecific anti-MUC16\/anti-death receptor 5 antibody achieves effective and tumor-selective death receptor 5-mediated tumor regression"],"prefix":"10.1038","volume":"15","author":[{"given":"Victor S.","family":"Goldmacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iosif","family":"Gershteyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Chari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yelena","family":"Kovtun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"93927_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1615\/CritRevEukarGeneExpr.v8.i3-4.50","volume":"8","author":"RA Farah","year":"1998","unstructured":"Farah, R. A., Clinchy, B., Herrera, L. & Vitetta, E. S. The development of monoclonal antibodies for the therapy of cancer. Crit. Rev. Eukar Gene Expr. 8, 321\u2013356 (1998).","journal-title":"Crit. Rev. Eukar Gene Expr"},{"key":"93927_CR2","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3390\/cells12242837","volume":"12","author":"M Delgado","year":"2023","unstructured":"Delgado, M. & Garcia-Sanz, J. A. Therapeutic monoclonal antibodies against cancer: present and future. Cells 12, 2837 (2023).","journal-title":"Cells"},{"key":"93927_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U. & Zhang, J. Antibody\u2013drug conjugates: a comprehensive review. Mol. Cancer Res. 18, 3\u201319 (2020).","journal-title":"Mol. Cancer Res."},{"key":"93927_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","volume":"24","author":"A Fenis","year":"2024","unstructured":"Fenis, A., Demaria, O., Gauthier, L., Vivier, E. & Narni-Mancinelli, E. New immune cell engagers for cancer immunotherapy. Nat. Rev. Immunol. 24, 471\u2013486 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"93927_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","volume":"36","author":"A Gajra","year":"2022","unstructured":"Gajra, A. et al. Barriers to chimeric antigen receptor T-Cell (CAR-T) therapies in clinical practice. Pharm. Med. 36, 163\u2013171 (2022).","journal-title":"Pharm. Med."},{"key":"93927_CR6","doi-asserted-by":"publisher","DOI":"10.2174\/0115748863286774240219094217","author":"B Khushboo","year":"2024","unstructured":"Khushboo, B. & Kumar, J. R. Perils and problems in bispecific T-Cell engager antibodies. Curr. Drug Saf. https:\/\/doi.org\/10.2174\/0115748863286774240219094217 (2024).","journal-title":"Curr. Drug Saf."},{"key":"93927_CR7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/abt\/tbae024","volume":"7","author":"VS Goldmacher","year":"2024","unstructured":"Goldmacher, V. S., Gershteyn, I. M. & Kovtun, Y. Beyond ADCs: Harnessing bispecific antibodies to directly induce apoptosis for targeted tumor eradication. Antib. Therapeut. 7, 361\u2013360 (2024).","journal-title":"Antib. Therapeut"},{"key":"93927_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein, C. et al. The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug Discov. 23, 301\u2013319 (2024).","journal-title":"Nat. Rev. Drug Discov"},{"key":"93927_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0955-0674(99)80034-9","volume":"11","author":"A Ashkenazi","year":"1999","unstructured":"Ashkenazi, A. & Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell. Biol. 11, 255\u2013260 (1999).","journal-title":"Curr. Opin. Cell. Biol."},{"key":"93927_CR10","doi-asserted-by":"publisher","first-page":"21265","DOI":"10.1074\/jbc.M111.306480","volume":"287","author":"CC Valley","year":"2012","unstructured":"Valley, C. C. et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. J. Biol. Chem. 287, 21265\u201321278 (2012).","journal-title":"J. Biol. Chem."},{"key":"93927_CR11","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1158\/0008-5472.CAN-15-1050","volume":"75","author":"S Das","year":"2015","unstructured":"Das, S. & Batra, S. K. Understanding the unique attributes of MUC16 (CA125): potential implications in targeted therapy. Cancer Res. 75, 4669\u20134674 (2015).","journal-title":"Cancer Res."},{"key":"93927_CR12","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1158\/0008-5472.CAN-06-4512","volume":"67","author":"Y Chen","year":"2007","unstructured":"Chen, Y. et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 67, 4924\u20134932 (2007).","journal-title":"Cancer Res."},{"key":"93927_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1480","volume":"26","author":"JR Junutula","year":"2008","unstructured":"Junutula, J. R. et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925\u2013932 (2008).","journal-title":"Nat. Biotechnol."},{"key":"93927_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1006\/jmbi.1999.3196","volume":"294","author":"S Jung","year":"1999","unstructured":"Jung, S., Honegger, A. & Pl\u00fcckthun, A. Selection for improved protein stability by phage display. J. Mol. Biol. 294, 163\u2013180 (1999).","journal-title":"J. Mol. Biol."},{"key":"93927_CR15","doi-asserted-by":"crossref","unstructured":"Li, F. & Ravetch, J. V. Antitumor activities of agonistic anti-TNFR antibodies require differential Fc\u03b3RIIB coengagement in vivo. Proc. Natl. Acad. Sci. U.S.A. 110, 19501\u201319506 (2013).","DOI":"10.1073\/pnas.1319502110"},{"key":"93927_CR16","doi-asserted-by":"crossref","unstructured":"Bournazos, S., Wang, T. T. & Ravetch, J. V. The role and function of Fc\u03b3 receptors on myeloid cells. Microbiol. Spectr. 4, (2016). 4.6.20.","DOI":"10.1128\/microbiolspec.MCHD-0045-2016"},{"key":"93927_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccell.2018.07.005","volume":"34","author":"G Shivange","year":"2018","unstructured":"Shivange, G. et al. A Single-Agent Dual-Specificity targeting of FOLR1 and DR5 as an effective strategy for ovarian cancer. Cancer Cell. 34, 331\u2013345 (2018).","journal-title":"Cancer Cell."},{"key":"93927_CR18","doi-asserted-by":"publisher","first-page":"e0260954","DOI":"10.1371\/journal.pone.0260954","volume":"16","author":"I Wilkinson","year":"2021","unstructured":"Wilkinson, I. et al. Fc-engineered antibodies with immune effector functions completely abolished. PLoS ONE. 16, e0260954 (2021).","journal-title":"PLoS ONE"},{"key":"93927_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature06106","volume":"449","author":"AJ Hessell","year":"2007","unstructured":"Hessell, A. J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101\u2013104 (2007).","journal-title":"Nature"},{"key":"93927_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1006\/cimm.2000.1617","volume":"200","author":"D Xu","year":"2000","unstructured":"Xu, D. et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell. Immunol. 200, 16\u201326 (2000).","journal-title":"Cell. Immunol."},{"key":"93927_CR21","doi-asserted-by":"publisher","first-page":"896","DOI":"10.4161\/mabs.26436","volume":"5","author":"MK Leabman","year":"2013","unstructured":"Leabman, M. K. et al. Effects of altered Fc\u03b3R binding on antibody pharmacokinetics in cynomolgus monkeys. mAbs 5, 896\u2013903 (2013).","journal-title":"mAbs"},{"key":"93927_CR22","doi-asserted-by":"crossref","unstructured":"Li, F. & Ravetch, J. V. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc\u03b3 receptor engagement. Proc. Natl. Acad. Sci. U.S.A. 109, 10966\u201310971 (2012).","DOI":"10.1073\/pnas.1208698109"},{"key":"93927_CR23","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.4049\/jimmunol.1101135","volume":"187","author":"AL White","year":"2011","unstructured":"White, A. L. et al. Interaction with Fc\u03b3RIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187, 1754\u20131763 (2011).","journal-title":"J. Immunol."},{"key":"93927_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/1535-7163.MCT-20-0253","volume":"20","author":"JM Garcia-Martinez","year":"2021","unstructured":"Garcia-Martinez, J. M. et al. Selective tumor cell apoptosis and tumor regression in CDH17-positive colorectal cancer models using BI 905711, a novel liver-sparing TRAILR2 agonist. Mol. Cancer Ther. 20, 96\u2013108 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"93927_CR25","unstructured":"US Patent 7723485."},{"key":"93927_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1208\/s12248-021-00647-0","volume":"23","author":"D Bussing","year":"2021","unstructured":"Bussing, D. et al. Pharmacokinetics of monoclonal antibody and antibody fragments in the mouse eye following systemic administration. AAPS J. 23, 116 (2021).","journal-title":"AAPS J."},{"key":"93927_CR27","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","volume":"76","author":"F Li","year":"2016","unstructured":"Li, F. et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 76, 2710\u20132719 (2016).","journal-title":"Cancer Res."},{"key":"93927_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/pros.22916","volume":"75","author":"VA DiPippo","year":"2015","unstructured":"DiPippo, V. A. et al. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. Prostate 75, 303\u2013313 (2015).","journal-title":"Prostate"},{"key":"93927_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/eji.1830030213","volume":"3","author":"J Bloemmen","year":"1973","unstructured":"Bloemmen, J. & Eyssen, H. Immunoglobulin levels of sera of genetically thymusless (nude) mice. Eur. J. Immunol. 3, 117\u2013118 (1973).","journal-title":"Eur. J. Immunol."},{"key":"93927_CR30","first-page":"539","volume":"40","author":"JG Mink","year":"1980","unstructured":"Mink, J. G. et al. Serum immunoglobulins in nude mice and their heterozygous littermates during ageing. Immunology 40, 539\u2013545 (1980).","journal-title":"Immunology"},{"key":"93927_CR31","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1038\/s41598-017-02483-9","volume":"7","author":"Y Zhu","year":"2017","unstructured":"Zhu, Y. et al. Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. Sci. Rep. 7, 2602 (2017).","journal-title":"Sci. Rep."},{"key":"93927_CR32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/1535-7163.MCT-15-0647","volume":"15","author":"P Brunker","year":"2016","unstructured":"Brunker, P. et al. RG7386, a novel tetravalent FAP-DR5 antibody, effectively triggers FAP-dependent, avidity-driven DR5 hyperclustering and tumor cell apoptosis. Mol. Cancer Ther. 15, 946\u2013957 (2016).","journal-title":"Mol. Cancer Ther."},{"issue":"1 Suppl","key":"93927_CR33","doi-asserted-by":"publisher","first-page":"AbstractA092","DOI":"10.1158\/1535-7163.TARG-17-A092","volume":"17","author":"J Bendell","year":"2018","unstructured":"Bendell, J. et al. Phase 1 trial of RO6874813, a novel bispecific FAP-DR5 antibody, in patients with solid tumors. Mol. Cancer Ther. 17 (1 Suppl), AbstractA092 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"93927_CR34","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1158\/1535-7163.MCT-20-0044","volume":"19","author":"MB Overdijk","year":"2020","unstructured":"Overdijk, M. B. et al. Dual epitope targeting and enhanced hexamerization by DR5 antibodies as a novel approach to induce potent antitumor activity through DR5 agonism. Mol. Cancer Ther. 19, 2126\u20132138 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"93927_CR35","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1182\/bloodadvances.2020003731","volume":"5","author":"HJ van der Horst","year":"2021","unstructured":"van der Horst, H. J. et al. Potent preclinical activity of HexaBody-DR5\/DR5 in relapsed and\/or refractory multiple myeloma. Blood Adv. 5, 2165\u20132172 (2021).","journal-title":"Blood Adv."},{"key":"93927_CR36","doi-asserted-by":"publisher","first-page":"2438173","DOI":"10.1080\/19420862.2024.2438173","volume":"16","author":"P Jung","year":"2024","unstructured":"Jung, P. et al. A TRAILR2\/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer. MABS 16, 2438173 (2024).","journal-title":"MABS"},{"key":"93927_CR37","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS820","volume":"41","author":"S Kopetz","year":"2023","unstructured":"Kopetz, S. et al. A phase Ia\/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers. J. Clin. Oncol. 41, 4_suppl TPS820, 820 (2023).","journal-title":"J. Clin. Oncol."},{"key":"93927_CR38","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1186\/s12885-023-11489-8","volume":"23","author":"Z Xia","year":"2023","unstructured":"Xia, Z. et al. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial. BMC Cancer. 23, 980 (2023).","journal-title":"BMC Cancer"},{"key":"93927_CR39","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1158\/0008-5472.CAN-20-2178","volume":"81","author":"DC Phillips","year":"2021","unstructured":"Phillips, D. C. et al. Hexavalent TRAIL fusion protein eftozanermin alfa optimally clusters apoptosis-inducing TRAIL receptors to induce on-target antitumor activity in solid tumors. Cancer Res. 81, 3402\u20133414 (2021).","journal-title":"Cancer Res."},{"key":"93927_CR40","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1158\/1535-7163.MCT-20-1132","volume":"20","author":"BT Wang","year":"2021","unstructured":"Wang, B. T. et al. Multimeric anti-DR5 IgM agonist antibody IGM-8444 is a potent inducer of cancer cell apoptosis and synergizes with chemotherapy and BCL-2 inhibitor ABT-199. Mol. Cancer Ther. 20, 2483\u20132494 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"93927_CR41","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1158\/1078-0432.CCR-23-0974","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. et al. Preclinical characterization and phase I trial results of INBRX-109, a third-generation, recombinant, humanized, death receptor 5 agonist antibody, in chondrosarcoma. Clin. Cancer Res. 29, 2988\u20133003 (2023).","journal-title":"Clin. Cancer Res."},{"key":"93927_CR42","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40265-024-02004-9","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon, S. Aponermin:\u00a0first approval.\u00a0Drugs 84, 459\u2013466 (2024).","journal-title":"Drugs"},{"key":"93927_CR43","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/modpathol.3800646","volume":"19","author":"SC Chauhan","year":"2006","unstructured":"Chauhan, S. C. et al. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod. Pathol. 19, 1386\u20131394 (2006).","journal-title":"Mod. Pathol."},{"key":"93927_CR44","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.humpath.2015.03.008","volume":"46","author":"M Iwamoto","year":"2015","unstructured":"Iwamoto, M., Nakatani, Y., Fugo, K., Kishimoto, T. & Kiyokawa, T. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium. Hum. Pathol. 46, 957\u2013962 (2015).","journal-title":"Hum. Pathol."},{"key":"93927_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ygyno.2005.06.040","volume":"99","author":"DG Rosen","year":"2005","unstructured":"Rosen, D. G. et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99, 267\u2013277 (2005).","journal-title":"Gynecol. Oncol."},{"key":"93927_CR46","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13000-021-01093-4","volume":"16","author":"S Kakimoto","year":"2021","unstructured":"Kakimoto, S. et al. Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis. Diagn. Pathol. 16, 28 (2021).","journal-title":"Diagn. Pathol."},{"key":"93927_CR47","first-page":"3906","volume":"23","author":"I Lakshmanan","year":"2017","unstructured":"Lakshmanan, I. et al. MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53. Clin. Cancer Res. 23, 3906\u20133917 (2017).","journal-title":"Cancer Res."},{"key":"93927_CR48","doi-asserted-by":"crossref","unstructured":"Tu, J. et al. Expression of mucin family proteins in non-small-cell lung cancer and its role in evaluation of prognosis. J. Oncol. 2022, 4181658 (2022).","DOI":"10.1155\/2022\/4181658"},{"key":"93927_CR49","doi-asserted-by":"publisher","first-page":"12226","DOI":"10.18632\/oncotarget.24203","volume":"9","author":"M Kanwal","year":"2018","unstructured":"Kanwal, M., Ding, X. J., Song, X., Zhou, G. B. & Cao, Y. MUC16 overexpression induced by gene mutations promotes lung cancer cell growth and invasion. Oncotarget 9, 12226\u201312239 (2018).","journal-title":"Oncotarget"},{"key":"93927_CR50","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/PAI.0000000000000368","volume":"25","author":"K Jiang","year":"2017","unstructured":"Jiang, K. et al. Cancer antigen 125 (CA125, MUC16) protein expression in the diagnosis and progression of pancreatic ductal adenocarcinoma. Appl. Immunohistochem. Mol. Morphol. 25, 620\u2013623 (2017).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"93927_CR51","doi-asserted-by":"publisher","first-page":"e26839","DOI":"10.1371\/journal.pone.0026839","volume":"6","author":"D Haridas","year":"2011","unstructured":"Haridas, D. et al. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS ONE. 6, e26839 (2011).","journal-title":"PLoS ONE"},{"key":"93927_CR52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12967-018-1632-2","volume":"16","author":"N Jonckheere","year":"2018","unstructured":"Jonckheere, N. & Van Seuningen, I. Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4\/MUC16\/MUC20 signature is associated with poor survival in human carcinomas. J. Transl Med. 16, 259 (2018).","journal-title":"J. Transl Med."},{"key":"93927_CR53","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/bjc.1988.251","volume":"58","author":"F Macdonald","year":"1988","unstructured":"Macdonald, F., Downing, R. & Allum, W. Expression of CA125 in pancreatic carcinoma and chronic pancreatitis. Br. J. Cancer. 58, 505\u2013506 (1988).","journal-title":"Br. J. Cancer"},{"key":"93927_CR54","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.humpath.2012.01.005","volume":"43","author":"MM Streppel","year":"2012","unstructured":"Streppel, M. M. et al. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum. Pathol. 43, 1755\u20131763 (2012).","journal-title":"Hum. Pathol."},{"key":"93927_CR55","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1097\/MPA.0b013e318221bed8","volume":"40","author":"T Einama","year":"2011","unstructured":"Einama, T. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas 40, 1276\u20131282 (2011).","journal-title":"Pancreas"},{"key":"93927_CR56","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.biocel.2007.05.013","volume":"39","author":"JR Davies","year":"2007","unstructured":"Davies, J. R., Kirkham, S., Svitacheva, N., Thornton, D. J. & Carlstedt, I. MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells. Int. J. Biochem. Cell. Biol. 39, 1943\u20131954 (2007).","journal-title":"Internat J. Biochem. Cell. Biol."},{"key":"93927_CR57","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1093\/humrep\/deu146","volume":"29","author":"N Dharmaraj","year":"2014","unstructured":"Dharmaraj, N. et al. Expression of the transmembrane mucins, MUC1, MUC4 and MUC16, in normal endometrium and in endometriosis. Hum. Reprod.\u00a029, 1730\u20131738 (2014).","journal-title":"Hum. Reproduct"},{"key":"93927_CR58","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/annonc\/mdw401","volume":"27","author":"JF Liu","year":"2016","unstructured":"Liu, J. F. et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody\u2013drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann. Oncol. 27, 2124\u20132130 (2016).","journal-title":"Ann. Oncol."},{"key":"93927_CR59","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ygyno.2021.09.023","volume":"163","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol. Oncol. 163, 473\u2013480 (2021).","journal-title":"Gynecol. Oncol."},{"key":"93927_CR60","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1096\/fj.14-257352","volume":"28","author":"D Haridas","year":"2014","unstructured":"Haridas, D. et al. MUC16: molecular analysis and its functional implications in benign and malignant conditions. FASEB J. 28, 4183\u20134199 (2014).","journal-title":"FASEB J."},{"key":"93927_CR61","doi-asserted-by":"publisher","first-page":"100821","DOI":"10.1016\/j.esmoop.2023.100821","volume":"8","author":"KN Moore","year":"2023","unstructured":"Moore, K. N. et al. 41P phase I analysis of Ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer. ESMO Open. 8, Suppl. 1, 100821 (2023).","journal-title":"ESMO Open."},{"key":"93927_CR62","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2020.06.089","volume":"159","author":"RE O\u2019Cearbhaill","year":"2020","unstructured":"O\u2019Cearbhaill, R. E. et al. A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC). Gynecol. Onc. 159, Suppl. 1, 42 (2020).","journal-title":"Gynecol. Onc"},{"key":"93927_CR63","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1158\/1078-0432.CCR-07-0950","volume":"13","author":"R Plummer","year":"2007","unstructured":"Plummer, R. et al. Phase 1 and Pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 13, 6187\u20136194 (2007).","journal-title":"Clin. Cancer Res."},{"key":"93927_CR64","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/annonc\/mdp292","volume":"21","author":"HA Wakelee","year":"2009","unstructured":"Wakelee, H. A. et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann. Oncol. 21, 376\u2013381 (2009).","journal-title":"Ann. Oncol."},{"key":"93927_CR65","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.2023.41.4_suppl.115","volume":"41","author":"JJ Harding","year":"2023","unstructured":"Harding, J. J. et al. A phase Ia\/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers. J. Clin. Oncol. 41, No. 4 Suppl. 115 (2023).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93927-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93927-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93927-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T17:00:20Z","timestamp":1743958820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93927-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93927"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93927-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are affiliated with ImmuVia Inc. IMV-M is currently under development at ImmuVia Inc. as a potential oncology drug candidate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9909"}}